NCT05409300View on ClinicalTrials.gov

Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

August 3, 2023

Study Completion Date

February 28, 2025

Conditions
COVID-19Vaccine Adverse ReactionSars-CoV-2 InfectionHealthy Volunteer
Interventions
BIOLOGICAL

BBIBP-CorV

Inactivated COVID19 vaccine, adjuvanted with aluminum hydroxide

Trial Locations (2)

Unknown

Centre de recherche de Landreah, Conakry

Palais du Peuple, Conakry

All Listed Sponsors
collaborator

CEPI

OTHER

collaborator

Alliance for International Medical Action

OTHER

collaborator

Centre National de Formation et de Recherche en Sante Rurale

OTHER_GOV

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

APHP

OTHER

collaborator

Agence Nationale de Sécurité Sanitaire de la Guinée (ANSS Guinée)

UNKNOWN

collaborator

Innovative clinical research network in vaccinology (IREIVAC)

UNKNOWN

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV